BiotechTube

Ustekinumab

Pre-clinicalRecruiting
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Crohn Disease

Conditions

Crohn Disease, Stricture; Bowel, Intestinal Stricture

Trial Timeline

Aug 1, 2024 → Aug 1, 2028

NCT ID
NCT05387031

About Ustekinumab

Ustekinumab is a pre-clinical stage product being developed by Sun Pharmaceutical for Crohn Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05387031. Target conditions include Crohn Disease, Stricture; Bowel, Intestinal Stricture.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT05387031Pre-clinicalRecruiting

Competing Products

20 competing products in Crohn Disease

See all competitors
ProductCompanyStageHype Score
VTX958 + VTX958 + VTX958 PlaceboVentyx BiosciencesPhase 2
47
LY4395089 + Mirikizumab - Intravenous (IV) + Mirikizumab - Subcutaneous (SC)Eli LillyPhase 2
52
CT-P13 + RemicadeCelltrionPhase 3
77
Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)CelltrionApproved
85
Ustekinumab 45 mg + Ustekinumab 90 mgCelltrionPre-clinical
23
CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13CelltrionPhase 1
33
CT-P13 SC (Infliximab)CelltrionPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
CP-461Astellas PharmaPhase 2
52
E6011 2 mg/kg + E6011 5 mg/kg + E6011 10 mg/kg + E6011 15 mg/kgEisaiPhase 1/2
41
E6011 + PlaceboEisaiPhase 2
52
E6011 + PlaceboEisaiPhase 1
33
adalimumab + adalimumab + placeboEisaiPhase 2/3
65
adalimumabEisaiPhase 2/3
65
Mirikizumab + Mirikizumab + Ustekinumab + Ustekinumab + Placebo + PlaceboEli LillyPhase 3
77
MirikizumabEli LillyPhase 3
77
Mirikizumab + Mirikizumab + Tirzepatide + PlaceboEli LillyPhase 3
77
Mirikizumab + PlaceboEli LillyPhase 2
52
MirikizumabEli LillyPhase 3
77

Other Products from Sun Pharmaceutical

Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85